From the Guidelines
Bentralizumab is not currently approved for treating Crohn's disease, and its effect on the condition is unknown, as it is an investigational monoclonal antibody primarily being studied for cancer immunotherapy, not inflammatory bowel diseases like Crohn's. For Crohn's disease, established treatments include anti-TNF agents (infliximab, adalimumab), anti-integrin therapies (vedolizumab), IL-12/23 inhibitors (ustekinumab), and JAK inhibitors (upadacitinib) 1. These medications work by targeting specific inflammatory pathways involved in Crohn's disease pathogenesis. Some key points to consider in the treatment of Crohn's disease include:
- Vedolizumab is recommended for induction of response and remission in patients with moderate-to-severe Crohn’s disease with inadequate response to conventional therapy and/or to anti-TNF therapy 1
- Vedolizumab is also recommended for maintaining clinical remission in patients with moderate-to-severe Crohn’s disease who achieved remission with vedolizumab 1
- Ustekinumab can be used in the induction and maintenance of remission of Crohn’s disease, both in anti-TNF naïve patients and in those where anti-TNF treatment fails 1 Treatment selection depends on disease severity, location, behavior, and individual patient factors. Patients with Crohn's disease should work with gastroenterologists to determine the most appropriate therapy based on their specific disease characteristics, previous treatment responses, and comorbidities. If you're interested in emerging therapies for Crohn's disease, several new biologics and small molecules are in clinical trials, but bentalizumab is not among the medications being actively investigated for this condition.
From the Research
Effect of Bentralizumab (Benzylamine) on Crohn's Disease
There are no research papers to assist in answering this question, as none of the provided studies mention Bentralizumab (Benzylamine) in the context of Crohn's disease.
Alternative Treatments for Crohn's Disease
- Infliximab is indicated for treatment of signs and symptoms, and induction and maintenance of remission in patients with moderate to severely active inflammatory Crohn's disease 2
- Vedolizumab may be effective in inducing clinical remission in patients with Crohn's disease who have failed previous TNF antagonist treatment, with therapeutic benefits detectable at week 10 3
- A network meta-analysis suggests that infliximab with azathioprine or adalimumab may be preferred as a first-line therapy for induction of clinical remission in patients with moderate-to-severe Crohn's disease 4
- Ustekinumab and vedolizumab have been compared as second-line therapies in patients with Crohn's disease who have failed TNF-alpha inhibitors, with vedolizumab associated with a higher rate of clinical remission at 1 year 5
- Traditional drugs such as corticosteroids, antibiotics, and immunosuppressors are also used in the treatment of moderate to severe Crohn's disease 6